In an osteoporosis context, administration of GLP-1R agonists, particularly exendin-4, reduced glucose, triglycerides, and total cholesterol levels in plasma [70] but increased osteocalcin gene expression and ratio of OPG to RANKL levels, all in favour of a beneficial role of GLP-1 in bone formation and protection [70]. The gene discussed is GLP1R; the disease is osteoporosis.